Status:
COMPLETED
Effect of Changes in Dialysate Bicarbonate on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients
Lead Sponsor:
Prim. Priv. Doz. Dr. Daniel Cejka
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal disease patients on chronic hemodiaysis.
Detailed Description
This single-arm, proof-of-principle study will be conducted at the dialysis facility of the Ordensklinikum Linz Elisabethinen Hospital. The dialysate bicarbonate prescription will be decreased from st...
Eligibility Criteria
Inclusion
- age ≥18 years
- chronic (≥3 months) treatment with hemodialysis or hemodiafiltration
- stable clinical condition
Exclusion
- inability to provide informed consent
- dialysis treatment less than thrice weekly
- morbid obesity (body mass index \>40 kg/m2)
- chronic inflammation (C reactive protein \>10 mg/dL, reference: \<0.5 g/dL)
- current immunosuppressive medication,
- severe chronic obstructive pulmonary disease (COPD stage III or IV)
- history of severe hypercapnia or hypoxemia
- overt congestive heart failure
- history of severe hypokalemia (\<3.0 mmol/l) or hyperkalemia (\>6.5 mmol/L) within 3 months prior to study inclusion.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2024
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT06084858
Start Date
October 1 2023
End Date
August 1 2024
Last Update
August 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ordensklinikum Linz GmbH Elisabethinen
Linz, Upper Austria, Austria, 4020